Meeting
2021 Genitourinary Cancers Symposium
Cabazitaxel multiple rechallenge in metastatic castration-resistant prostate cancer: A therapeutic option to increase overall survival?
Authors
Cedric Pobel
Oncology department, Hôpital Européen Georges Pompidou, AP-HP, University of Paris, Paris, France
Cedric Pobel , Edouard Auclin , Diego Teyssonneau , Brigitte Laguerre , Mathilde Cancel , Elouen Boughalem , Johanna Noel , Pierre Emmanuel Brachet , Denis Maillet , Philippe Barthelemy , Carole Helissey , Constance Thibault , Stephane Oudard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 97)
DOI
10.1200/JCO.2021.39.6_suppl.97
Abstract #
97
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Alice Clement-Zhao
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova
Poster
2023 ASCO Genitourinary Cancers Symposium
![Efficacy of systemic therapy following [<sup>177</sup>Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).](https://d201v5jt9ylckg.cloudfront.net/298/15164/217588/217588_A228_poster_pv.jpg)
Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Louise Kathleen Kostos
Poster
2023 ASCO Genitourinary Cancers Symposium
Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
First Author: Padmanee Sharma